EICHOR
● Recruiting
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
Condition: Atopic Dermatitis · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
About this study
This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.
This description comes directly from the study's public registry record.
Talk to the study team
Xin Li, PhD · 86-028-67255165 · lixin@kelun.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Huashan Hospital Affiliated to Fudan University | Shanghai, China | Recruiting |
| Huashan Hospital Affiliated to Fudan University | Shanghai, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07488065